Anti-NASH Drug Development Hitches a Lift on PPAR Agonism

Non-alcoholic fatty liver disease (NAFLD) affects one-third of the population worldwide, of which a substantial number of patients suffer from non-alcoholic steatohepatitis (NASH). NASH is a severe condition characterized by steatosis and concomitant liver inflammation and fibrosis, for which no dru...

Descripción completa

Detalles Bibliográficos
Autores principales: Boeckmans, Joost, Natale, Alessandra, Rombaut, Matthias, Buyl, Karolien, Rogiers, Vera, De Kock, Joery, Vanhaecke, Tamara, Rodrigues, Robim M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7016963/
https://www.ncbi.nlm.nih.gov/pubmed/31877771
http://dx.doi.org/10.3390/cells9010037

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7016963/
https://www.ncbi.nlm.nih.gov/pubmed/31877771
http://dx.doi.org/10.3390/cells9010037

Ejemplares similares